|Series A, 2/2012 |
Access BridgeGap Ventures
Slater Technology Fund
|Series A, 6/2013 |
Mnemosyne Pharmaceuticals, Inc. is developing an innovative drug discovery platform that will address medical needs in several segments of the mental health market.
Mnemosyne was founded in 2010 with seed funding from Slater Technology Fund and private investors. Recently, Mnemosyne closed on a Series A round totaling $5.4M. Mnemosyne is using these funds to develop a new class of small molecule drugs that modulate the activity of different subtypes of the NMDA receptor.